FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987710088> ?p ?o ?g. }

• W1987710088 endingPage "2" @default.
• W1987710088 startingPage "1" @default.
• W1987710088 abstract "In 1906, Alois Alzheimer first documented the case of Auguste Deter, a patient with a combination of cognitive deficits, psychiatric symptoms, and microscopic brain lesions. This histopathological and clinical constellation was then designated by Emil Kraepelin as Alzheimer's disease (AD) [1]. Nowadays, AD became the most common progressive neurodegenerative disease and the most common form of dementia among the elderly [2, 3]. In the clinic, the late-onset AD (LOAD) accounts for 95% of all AD cases and is currently considered as a genetic complex disorder that is probably caused by a combination of multiple risk alleles and environmental factors [4]. To date, APOE is the only unequivocally established susceptibility gene for LOAD [5]. However, it has been estimated that the variations of APOE account for less than 50% of LOAD risk, suggesting that there are additional genetic risk factors which remain to be uncovered. Recent advances in genetic approaches led to the identification of numerous risk genes for AD, which has greatly extended our knowledge on the genetic components of this disease [6]. In this special issue, the paper entitled “Clinical Genetics of Alzheimer's Disease” by Z. Zou et al. outlined these novel susceptibility genes, such as CLU, CR1, CD33, PICALM, BIN1, TREM2, and PLD3. More importantly, they summarized the recent evidence regarding the functions of these genes as well as their association with phenotypes and pathogenesis of AD. This allowed readers to get a good understanding on the research advances in the genetic basis and pathological mechanisms of this devastating disease.Regarding the neuropathology, AD is mainly characterized by the formation of extracellular neuritic plaques containing the amyloid-β peptide (Aβ) and intraneuronal accumulation of neurofibrillary tangles constituted by hyperphosphorylated tau protein. In 2002, John Hardy proposed “amyloid hypothesis,” which emphasized Aβ accumulation as the initial pathological events in the progression of AD [7]. Therefore, therapeutic strategies against Aβ, especially Aβ-induced neurotoxicity, have attracted a lot of attention in recent years. In the current issue, by employing primary neuron culture, C.-F. Lau et al. provided the first evidence that testosterone could protect against Aβ-induced synaptic dysfunction and degeneration in “Protective Effects of Testosterone on Presynaptic Terminals against Oligomeric β-Amyloid Peptide in Primary Culture of Hippocampal Neurons.” These exciting findings emphasized testosterone as a potential endogenous target of drug development, which might open up a new avenue for the prevention and treatment of AD. Additionally, in this issue, another original paper entitled “Inhibitory Effects of Edaravone in β-Amyloid-Induced Neurotoxicity in Rats” by F. He et al. provided preclinical evidence concerning the beneficial effects of edaravone, a free radical scavenger mainly used for stoke treatment, in an AD model induced by Aβ injection. For the first time, they showed that edaravone could attenuate Aβ-induced increase of voltage-gated calcium channel currents and cholinergic neurons losses, which subsequently improved learning and memory performance. Their interesting finding implied that edaravone might have a practical clinical use for AD prevention and treatment, emphasizing the notion that many therapeutic agents possessed pleiotropic actions in addition to their main applications.In addition to its own neurotoxicity, Aβ as the central pathological factor also initiates a series of secondary events in AD progression, such as neuroinflammation. Activation of microglia, the main immune cell in the brain, is considered as a central event in Aβ-induced neuroinflammation. Actually, several lines of evidence suggested a “double-edged sword” function of microglia during the progression of AD [8]. On one hand, long-term Aβ stimulation results in the dysfunction of microglia in the brain, which is characterized by the overproduction of proinflammatory cytokines, subsequently leading to the bystander neuronal and synaptic damage. On the other hand, activated microglia participates in the phagocytosis of Aβ through its phagocytic activity and thus prevents the deposition of Aβ and the formation of amyloid plaques. In this special issue, a review article entitled “Microglia in Alzheimer's Disease” by Y. Li et al. summarized the recent advances concerning microglia during AD progression. Meanwhile, they also introduced the recent basic and clinic efforts regarding how to prevent and treat this disease via precise modulation of microglial functions. Their contributions will greatly help the readers to get a better understanding on the role of microglia and neuroinflammation in the mechanisms and therapeutics of AD.In summary, the articles in this issue cover the recent progress in the genetic basis and molecular mechanisms underlying AD pathogenesis, accompanied with the development of diagnostic approaches and therapeutic strategies for this disease. We hope that the reader will extend their knowledge about the basic and clinical aspects of AD through this collection of articles.Teng JiangRaymond Chuen-Chung ChangHanna RosenmannJin-Tai Yu" @default.
• W1987710088 created "2016-06-24" @default.
• W1987710088 creator A5003518754 @default.
• W1987710088 creator A5005450037 @default.
• W1987710088 creator A5060887077 @default.
• W1987710088 creator A5071624932 @default.
• W1987710088 date "2015-01-01" @default.
• W1987710088 modified "2023-10-02" @default.
• W1987710088 title "Advances in Alzheimer’s Disease: From Bench to Bedside" @default.
• W1987710088 cites W1484890431 @default.
• W1987710088 cites W202790951 @default.
• W1987710088 cites W2036735444 @default.
• W1987710088 cites W2082429191 @default.
• W1987710088 cites W2096410114 @default.
• W1987710088 cites W2097112082 @default.
• W1987710088 cites W2105557181 @default.
• W1987710088 cites W2158139560 @default.
• W1987710088 cites W2164201168 @default.
• W1987710088 doi "https://doi.org/10.1155/2015/202676" @default.
• W1987710088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4350579" @default.
• W1987710088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25789309" @default.
• W1987710088 hasPublicationYear "2015" @default.
• W1987710088 type Work @default.
• W1987710088 sameAs 1987710088 @default.
• W1987710088 citedByCount "6" @default.
• W1987710088 countsByYear W19877100882015 @default.
• W1987710088 countsByYear W19877100882018 @default.
• W1987710088 countsByYear W19877100882020 @default.
• W1987710088 countsByYear W19877100882021 @default.
• W1987710088 countsByYear W19877100882022 @default.
• W1987710088 crossrefType "journal-article" @default.
• W1987710088 hasAuthorship W1987710088A5003518754 @default.
• W1987710088 hasAuthorship W1987710088A5005450037 @default.
• W1987710088 hasAuthorship W1987710088A5060887077 @default.
• W1987710088 hasAuthorship W1987710088A5071624932 @default.
• W1987710088 hasBestOaLocation W19877100881 @default.
• W1987710088 hasConcept C142724271 @default.
• W1987710088 hasConcept C177713679 @default.
• W1987710088 hasConcept C19527891 @default.
• W1987710088 hasConcept C2779134260 @default.
• W1987710088 hasConcept C3020000666 @default.
• W1987710088 hasConcept C502032728 @default.
• W1987710088 hasConcept C60644358 @default.
• W1987710088 hasConcept C71924100 @default.
• W1987710088 hasConcept C86803240 @default.
• W1987710088 hasConceptScore W1987710088C142724271 @default.
• W1987710088 hasConceptScore W1987710088C177713679 @default.
• W1987710088 hasConceptScore W1987710088C19527891 @default.
• W1987710088 hasConceptScore W1987710088C2779134260 @default.
• W1987710088 hasConceptScore W1987710088C3020000666 @default.
• W1987710088 hasConceptScore W1987710088C502032728 @default.
• W1987710088 hasConceptScore W1987710088C60644358 @default.
• W1987710088 hasConceptScore W1987710088C71924100 @default.
• W1987710088 hasConceptScore W1987710088C86803240 @default.
• W1987710088 hasLocation W19877100881 @default.
• W1987710088 hasLocation W19877100882 @default.
• W1987710088 hasLocation W19877100883 @default.
• W1987710088 hasLocation W19877100884 @default.
• W1987710088 hasLocation W19877100885 @default.
• W1987710088 hasOpenAccess W1987710088 @default.
• W1987710088 hasPrimaryLocation W19877100881 @default.
• W1987710088 hasRelatedWork W1839838842 @default.
• W1987710088 hasRelatedWork W1980950179 @default.
• W1987710088 hasRelatedWork W2076985335 @default.
• W1987710088 hasRelatedWork W2090704721 @default.
• W1987710088 hasRelatedWork W2124125394 @default.
• W1987710088 hasRelatedWork W2736051916 @default.
• W1987710088 hasRelatedWork W2753550874 @default.
• W1987710088 hasRelatedWork W2991533465 @default.
• W1987710088 hasRelatedWork W3028982701 @default.
• W1987710088 hasRelatedWork W4281643853 @default.
• W1987710088 hasVolume "2015" @default.
• W1987710088 isParatext "false" @default.
• W1987710088 isRetracted "false" @default.
• W1987710088 magId "1987710088" @default.
• W1987710088 workType "article" @default.